Drug Profile
FY 304
Alternative Names: FY-304Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator YD Global Life Science
- Developer Hanrim University; YD Global Life Science
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Neuropathic pain in South Korea (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neuropathic-pain in South Korea
- 04 Jul 2016 Preclinical development is ongoing in South Korea